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Background: Glioblastomas are largely unresponsive to all available treatments and there is therefore an urgent need for
novel therapeutics. Here we have probed the antineoplastic effects of a bacterial protein toxin, the cytotoxic necrotizing
factor 1 (CNF1), in the syngenic GL261 glioma cell model. CNF1 produces a long-lasting activation of Rho GTPases, with
consequent blockade of cytodieresis in proliferating cells and promotion of neuron health and plasticity.
Methods: We have tested the antiproliferative effects of CNF1 on GL261 cells and human glioma cells obtained from
surgical specimens. For the in vivo experiments, we injected GL261 cells into the adult mouse visual cortex, and five days
later we administered either a single intracerebral dose of CNF1 or vehicle. To compare CNF1 with a canonical
antitumoral drug, we infused temozolomide (TMZ) via minipumps for 1 week in an additional animal group.
Results: In culture, CNF1 was very effective in blocking proliferation of GL261 cells, leading them to multinucleation,
senescence and death within 15 days. CNF1 had a similar cytotoxic effect in primary human glioma cells. CNF1 also
inhibited motility of GL261 cells in a scratch-wound migration assay. Low dose (2 nM) CNF1 and continuous TMZ infusion
significantly prolonged animal survival (median survival 35 days vs. 28 days in vehicle controls). Remarkably, increasing
CNF1 concentration to 80 nM resulted in a dramatic enhancement of survival with no obvious toxicity. Indeed, 57% of
the CNF1-treated animals survived up to 60 days following GL261 glioma cell transplant.
Conclusions: The activation of Rho GTPases by CNF1 represents a novel potential therapeutic strategy for the treatment
of central nervous system tumors.
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Gliomas are primary central nervous system tumors that
arise from astrocytes, oligodendrocytes or their precursors.
Following the World Health Organization (WHO) classifi-
cation, gliomas can be classified in 4 groups according to
their histological characteristics and the most malignant
form is glioblastoma multiforme (GBM). GBM is uniformly
fatal and largely unresponsive to all available treatments.
Despite intensive therapy including surgery, radiotherapy
and chemotherapy, the average of survival of patients with
glioblastoma usually is 15 months from the time of first* Correspondence: caleo@in.cnr.it
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unless otherwise stated.diagnosis [1,2]. Conventional surgical excision, generally
limited to the main tumor mass, does not remove the
microscopic foci of neoplastic cells that invade the sur-
rounding normal brain substance beyond the main tumor
mass, and that are responsible for the inevitable tumor re-
currence. Radiotherapy and chemotherapy, often associated
to surgery, cannot ablate completely these tumors, since
this would require unacceptably high radiation/che-
motherapic doses that result in severe brain-neuron dam-
age. There is therefore a clear need to accelerate progress
in the development of new strategies for treatment of
glioma.
Several therapeutic approaches for glioma are currently
being investigated in animal models and patients. They in-
clude delivery of cytotoxic genes and proteins to gliomaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[3]. Concerning chemotherapy, alkylating agents such as
temozolomide (TMZ) are widely used in the treatment of
brain tumours [4]. As a cytotoxic alkylating agent, TMZ is
converted at physiologic pH to the short-lived active
compound, monomethyl triazeno imidazole carboxamide
(MTIC). The cytotoxicity of MTIC is primarily due to
methylation of DNA at the O6 and N7 positions of
guanine, resulting in inhibition of DNA replication. Che-
motherapics have substantial side effects and limited effi-
cacy, and this further underlies the need of innovative
approaches for glioma treatment.
In this paper we describe a potential novel therapy for
glioma, based on intracerebral administration of cyto-
toxic necrotizing factor 1 (CNF1), a bacterial protein
toxin produced by specific strains of Escherichia coli.
CNF1 is a single-chain protein, consisting of a N-
terminal domain involved in cell binding, a middle
region mediating membrane translocation, and a C-
terminal catalytic domain. The C-terminal part of CNF1
is released into the cytosol where it catalyzes the deami-
dation of a single glutamine residue of the Rho GTPases
(RhoA, Rac1 and Cdc42). Rho GTPases are molecular
switches that cycle between a GDP-bound inactive and
a GTP-bound active state to control a multitude of cel-
lular events, like actin cytoskeleton organization as well
as gene transcription, cell proliferation, and survival [5].
Rho GTPases deamidated by CNF1 are not able to
hydrolyse GTP and remain in a persistent activated state
[6,7] which is followed by partial deactivation of these
regulatory proteins via degradation by the ubiquitin–prote-
asome pathway [8]. The persistent activation of Rho
GTPases by CNF1 causes a remarkable reorganization of
the actin cytoskeleton with dramatic functional conse-
quences. In particular, cultured proliferating cells exposed
to CNF1 acquire a multinucleated phenotype (cytotoxic ef-
fect), due to stabilization of the actin network and preven-
tion of cytodieresis despite ongoing nuclear division [9]. On
the other hand, our recent studies have demonstrated “plas-
ticizing” effects of CNF1 in neurons. Specifically, intracere-
bral administration of CNF1 improves neuronal function,
learning and memory [10,11], and these effects are associ-
ated with a enhancement of brain plasticity, exemplified by
the increase in spine density in cortical neurons [10].
In view of these striking, differential effects of CNF1 on
proliferating cells and neurons, we have probed for the first
time the potential antitumoral effects of this toxin in cell
culture and in an animal model. Among the available gli-
oma models, we adopted the well accepted GL261 syngen-
eic mouse model of high grade glioma [12,13] based on
intracerebral injection of GL261 cells in C57/Bl6 mice. We
demonstrate the cytostatic and cytotoxic effects of CNF1
on GL261 glioma cell line, and the survival-promoting ef-
fect on tumor-bearing animals. We have also providedproof-of-principle for cytotoxic effects of CNF1 in human
tumor cells.
Methods
GL261 glioma cell cultures
The murine glioma GL261 cell line was a kind gift from
Dr. C. Sala (CNR Neuroscience Institute, Milan). GL261
cells were grown in complete Dulbecco’s modified Ea-
gle’s medium (DMEM) containing 10% Newborn calf
serum, 4.5 g/L glucose, 2 mM glutamine, 100 UI/ml
penicillin and 100 mg/ml streptomycin at 37°C in 5%
CO2 with media changes three times per week.
CNF1
E. coli CNF1 was obtained from the 392 ISS strain
(kindly provided by V. Falbo, Istituto Superiore di Sanità,
Rome, Italy) and purified as described previously [14].
The levels of lipopolysaccharide (LPS) in the CNF1
preparation were assessed by the Limulus Amebocyte
Lysate (LAL) kinetic chromogenic assay (performed by
LONZA Verviers Sprl). The LPS concentration deter-
mined by the assay (0.07 ng/ml) was much lower than
that required to achieve biological effects (e.g. 1 ng/ml
in macrophages, one of the most sensitive cells to LPS).
The activity of every batch of CNF1 was tested on
GL261, treating the cells for 24 hours. Three parameters
were considered: i) cells morphology (enlargement and
flattening of cells), ii) increased size of nucleoli and iii)
the ratio between mono and multinucleated cells. The
activity of each CNF1 preparation was considered satis-
factory if at least one of the three parameters indicated
above were present in more than 60% of treated cells.
Clonogenic assay
GL261 cells were harvested by trypsinization, counted
and seeded onto twenty four-well plates at a density of
300 cells/plate. To assess the effect of CNF1 on cell pro-
liferation, GL261cells were incubated for 9 days with dif-
ferent concentrations of CNF1 (from 8 × 10−11 to 3.2 ×
10−9 M). Nine days after treatment, cells were stained
with crystal violet, the number of colonies containing at
least 50 cells was counted [15] and the effective half in-
hibitory dose (IC50) of the toxin was calculated on the
basis of linear regression equation.
Wound healing-migration assay
The wound healing migration assay was performed ac-
cording to Liang [16] with minor modifications. Briefly,
GL261 cells were seeded in 6-well cell plates and cul-
tured to a confluent monolayer. A sterile pipette tip
(200 μl) was used to make a straight scratch on the
monolayer of cells and the wound was allowed to heal
for 8, 24 and 48 hours. To evaluate CNF1 effects, GL261
cells were incubated with CNF1 for 24 hours before
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24 and 48 hours after the injury. The cells were then
fixed with methanol and stained with crystal violet. The
extent of cell migration was photographed and the
wound size measured using image analysis software
(ImageJ).
Apoptosis-necrosis assays
Apoptotic and/or necrotic cells were determined using
Annexin V- Propidium Iodide (PI) Staining Kit. The
assay was performed following the manufacturer instruc-
tions (Annexin V kit, BD Pharmingen). Briefly, 300
GL261 cells were seeded on twenty four-well plates and
incubated in CNF1 (18 nM) for 10 days. Annexin V and
Propidium Iodide were diluted 1:200 in KREB medium
(NaCl 120 mM, NaKCO3 25 mM, KCl 4.7 mM, KH2PO4
1.18 mM, MgSO4 1.18 mM, CaCl2 2.5 mM, EDTA
0.026 mM, glucose 5.5 mM). Cells were also stained with
Hoechst dye (bisbenzimide, Sigma; 1:500 in PBS) and
counted with fluorescence microscopy. We classified
cells as positive for annexin V only (Ann V + PI-), posi-
tive for PI only (Ann V- PI+), positive for both markers
(Ann V + PI+) or unlabeled.
Senescence-Associated Beta-Galactosidase (SA beta-gal)
Assay
To determine cellular senescence, GL261 cells were
plated in triplicate at low density (50% confluence) in
24-well plates. The cells were treated with CNF1 (1 nM)
and incubated for 24, 48 or 72 hours before beta-
galactosidase measure (senescence detection kit, Abcam
catalog ab65351). The percentage of positively stained
cells was determined after counting three random fields
of cells. Representative microscopic fields were photo-
graphed under a 20× objective.
Human glioblastoma cell cultures
Human biopsies of glioblastoma multiforme (GBM)
were collected from 2 subjects who underwent brain
surgery for tumor removal. The study was approved by
the Human Ethics Committee of the University of Pisa
and Pisa Hospital. Written, informed consent was ob-
tained from the patients according to institutional guide-
lines. Patient 1 had a left parietal lesion resembling a
high grade glioma on a contrast enhanced MRI scan,
while patient 2 had a similar lesion located in the left
fronto-parietal region. A surgical gross total resection
was performed and the histological examination con-
firmed the suspected tumor type (WHO grade IV) in
both cases. After collection, primary tumor cells were
isolated according to [17]. Briefly, tissue explants were
incubated with trypsin in DMEM for 10 minutes at 37°C
and then added of 3 volumes of DMEM with 10% FBS.
Tissue was completely disgregated by gentle pipetting.Cells suspension was then plated on tissue culture dishes
and culture medium (DMEM, 10%FBS, 100 IU/ml peni-
cillin,100 mg/ml streptomycin) was replaced every 3–5
days. After a week cells were trypsinized and splitted. At
passage five [18] cells were plated on cover slips and
then treated with 18nM CNF1 for 9 days. At this time
point, cells were fixed and stained to observe their
morphology.
Animals and tumor induction
To induce glioma formation, C57BL/6 mice (12–14 weeks
old) received a stereotaxically guided injection of 40,000
GL261 cells (20,000 cells/μl PBS solution) into the visual
cortex (2 mm lateral to the midline and in correspondence
with lambda) using fine glass micropipettes (tip diameter
40 μm). All experimental procedures were in conformity to
the European Communities Council Directive 86/609/EEC.
The animal experiments described in this manuscript have
been approved by the Italian Ministry of Health, Depart-
ment of Animal Health (Office n. 6), with decree #258-
2012/B, dated Oct 23, 2012.
CNF1 injections and TMZ minipumps
Five days after GL261 cells injection (tumor induction),
mice were divided into three groups. The first group re-
ceived CNF1 injection, the second Tris–HCl buffer in-
jection (control condition). Stereotaxic infusions of
CNF1/Tris–HCl (1 μl of a 2 or 80 nM solution) were
made into the primary visual cortex of adult mice under
avertin anesthesia (intraperitoneal injection of 2,2,2-tri-
bromoethanol solution; 0.1 ml/5 g body weight). Injec-
tions were performed in three sites: 1.5, 2 and 2.5 mm
lateral to the midline in correspondence with lambda.
CNF1/Tris–HCl injections was slowly delivered at a
depth of 0.7–0.8 mm from the pial surface.
The third experimental group received Temozolomide
(TMZ) micropumps implantation for a week. Minipump
implantation was performed as described previously
[19,20]. Micro-osmotic pumps (Alzet 1007D; Alza, USA;
pumping rate 0.5 μl/hr) were filled with TMZ (20, 140
and 200 μM solution) and connected with polyethylene
tubing to 30 G stainless steel cannulae [20]. A small hole
was made in the skull (2 mm lateral, 1 mm anterior) and
the cannula was lowered into the cortex. The minipump
was positioned subcutaneously under the neck and the
cannula was secured to the skull with acrylic cement.
Animals survival was checked daily and monitored up to
60 days after tumor implantation. At this time, mice that
were still alive were deeply anesthetized and perfused
with 4% paraformaldehyde. Coronal brain sections
through the occipital cortex (45 μm thick) were cut with
a freezing microtome, stained with Hoechst dye (1:500,
Sigma) and histopatological examinations were carried
out.
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Statistical analysis was performed with SigmaPlot (ver-
sion 11). Differences between three or more groups were
evaluated with one way analysis of variance (ANOVA)
followed by Holm-Sidak test.
Survival analysis was performed using Kaplan-Meier
(LogRank) statistics.
Results
CNF1 blocks GL261 cell proliferation in culture
We first used a clonogenic assay to determine whether
glioma cell proliferation is affected by CNF1. GL261
cells were plated at low density and exposed to different
concentrations of CNF1. Colonies were counted after
9 days. We found that CNF1 inhibits colony formation
in a dose-dependent manner (Figure 1). The half max-
imal inhibitory concentration (IC50) of CNF1 was found
to be 0.47 nM (Figure 1B). In subsequent experiments,
we always used CNF1 concentrations in the nanomolar
range to ensure robust effects on cell proliferation.
A short exposure time is sufficient for CNF1 to exert its
effects
In order to determine the minimal exposure time re-
quired by CNF1 to exert its effects, cells were treated
with CNF1 (18 nM) for different times (ranging from 1
up to 16 hours). At the end of each incubation time, theFigure 1 Clonogenic assay and inhibitory effect of CNF1 on
GL261 cells proliferation. (A) Representative images of a colony
assay of cells treated with vehicle (control) and increasing
concentrations of CNF1. (B) Quantification of the number of
colonies in the clonogenic assay for each CNF1 concentration. IC50
of the CNF1 toxin is 0.47 nM. All data represent means ± SEM (n = 3).toxin was replaced with fresh medium. Effects of the
toxin were evaluated by counting cell numbers five days
after treatment. The experiments demonstrated that
1 hour exposure to CNF1 was sufficient to stop prolifer-
ation, as shown by the dramatic (about 80%) reduction
in cell numbers as compared to control (no treatment)
conditions (one way ANOVA, p < 0.001; post hoc Holm-
Sidak test, p < 0.001; Figure 2A). CNF1 effects became
even more prominent by increasing the exposure time
to 16 hours (p < 0.001; Figure 2A). We also evaluated the
morphological appearance of the treated cells (Figure 2B).
We found that in control conditions all cells were
mononucleated, while in cells treated with CNF1 for 16
hours this phenotype decreased to 16%, and the percent-
age of multinucleated cells increased with longer CNF1
exposures (one way ANOVA, p < 0.001; post hoc Holm-
Sidak test, p < 0.001; Figure 2C).
CNF1 reduces the migration capability of GL261 cells
A wound healing assay was performed in the GL261
cells incubated in culture medium with or without
CNF1 (1 nM) to observe the effect of CNF1 on the mi-
gration. The area that the cells had migrated within 8,
24 and 48 hours (toward the initially scratched midline,
from the border line) was measured. The experiments
demonstrated that after 8 hours the number of cells mi-
grating in the wound increased in normally growing
cells, whereas fewer cells migrated in the wound area in
CNF1-treated cells. The treatment effect was more evi-
dent after 24 hours, when in control cells the wound
was healed to 80% whereas in CNF1-treated cells it was
closed to about 30% and, at 48 hours, in control the
wound was totally closed while in treated cells was half
closed (Figure 3A and B).
Fate of GL261 cells after prolonged CNF1 exposure
To determine the fate of polynucleated GL261, cells
were treated with CNF1 (18 nM) at day one and then
cultured without removal of the toxin for 15 days. We
found a clear cytostatic effect of CNF1 until day 12
(Figure 4A). At this time point, GL261 cells treated with
CNF1 still showed the characteristic altered morphology
(enlargement and flattening of cells, increased size
of nucleoli and multinucleation; see also Methods;
Figure 4A, inset). Importantly, treatment for 15 days re-
sulted in no survival of GL261 cells (Figure 4A), consist-
ent with a cytotoxic action of CNF1.
As a first step towards understanding the mechanisms
of CNF1-induced GL261 cell death, we stained cells with
markers of apoptosis and necrosis (annexin V and propi-
dium iodide, respectively) 10 days after treatment. We
chose this time point as it corresponds to a stage that
just precedes cell disappearance, however all cells are
still attached to dish and show the morphological
Figure 2 A brief CNF1 exposure is sufficient to stop cell
proliferation. (A) Percentage of living GL261 cells after different
time periods of CNF1 exposure. Data are normalized to the values
obtained in vehicle-treated control (Ctrl) cells. (B) Crystal violet
staining showing multinucleation of GL261 cells after 16 hours CNF1
exposure. Scale bar = 4 μm (C) Relative percentage of multinucleated
cells in dishes treated with vehicle (Ctrl) and CNF1 for different
periods. All data represent means ± SEM (n = 3).
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tosis, we used GL261 cells deprived of serum for 2 days,
which showed a robust increase in annexin V, but not PI
staining (Figure 4B, left columns, AnnV + PI-; one way
ANOVA followed by Holm-Sidak test, p < 0.05; Figure 4B,
grey bars). GL261 cells treated with CNF1 for 10 days
showed no clear evidence for either apoptotic (Figure 4B,left columns, “AnnV+PI-“) or necrotic cell death (Figure 4B,
“AnnV- PI+”). However, more than 50% of CNF1-
treated cells at 10 days resulted positive for both markers
(Figure 4B, “AnnV + PI+”; one way ANOVA followed by
Holm-Sidak test, p < 0.05) indicating profound cellular
distress and late stages of cell demise.
CNF1 induces early activation of senescence pathway
As indicated above, the GL261 cells treated with CNF1
are arrested in the cell proliferation and show a senes-
cent morphology (enlargement and flattening of cells).
We therefore adopted the β-Galactosidase activity, as a
well accepted senescence marker, to confirm our mor-
phological observation. The blue β-Galactosidase stain-
ing in treated cells was detectable as early as one day
after treatment with the toxin (1 nM), and became in-
tense and expressed in every cell of the culture after
72 hours. The SA-β-gal staining was not detected or
barely detected in untreated control cells (Figure 5).
CNF1-induced multinucleation in human primary tumoral
cells
To obtain proof-of-principle for CNF1 action on human
glioma cells, two surgical specimens were obtained from
patients with GBM (WHO grade IV). CNF1 effects (18
nM) were examined in early passages (five passages) cell
lines from these primary GBM specimens. Similar to
GL261 cells, we observed the CNF1-induction of multi-
nucleation in human tumor cells treated with the toxin
for 9 days (Figure 6).
Overall, these data indicate a powerful cytostatic and
cytotoxic effect of CNF1 on cultured glioma cells, in-
cluding tumor cells from human subjects.
Intracerebral CNF1 treatment enhances survival in a
murine glioma model
Prompted by the cytostatic and cytotoxic effects of
CNF1 in vitro, we tested the actions of this toxin after
intracerebral inoculation of GL261 cells in adult mice.
The murine GL261 model is a well accepted and widely
used syngeneic transplant model for experimental gli-
oma tumors, and reproduces many of the histopatho-
logical features of human glioma [12,13].
GL261 cells (40,000 cells in 2 μl) were transplanted at
the level of layer VI into the occipital (visual) cortex of
adult mice. Five days later, animals were injected around
the transplant site with either vehicle (TRIS buffer; n =
19) or CNF1 (2 nM; n = 9; Figure 7A top). This dose of
CNF1 has been previously shown to trigger a prolonged
activation of Rho GTPases (particularly, Rac1) in vivo
[10,11]. Kaplan-Meier survival analysis indicated a clear
survival-promoting effect of CNF1 when compared to
vehicle (Log Rank test, p = 0.02; Figure 7B).
Figure 3 Wound-healing migration assay of CNF1-treated Gl261 cells. (A) Representative images of wound in untreated cells (left column)
and CNF1-treated cells (right column) at different time points (0, 8, 24 and 48 hours). The data demonstrate the inability of CNF1-treated cells to
invade the wound area. (B) Quantitative plots of the wound size at different time points in the two conditions (CNF1 and control). Data shown
are representative of three independent experiments. All data represent means ± SEM. (two-way ANOVA, **p < 0.001). Scale bar = 100 μm.
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To directly compare the actions of CNF1 with those of
classical chemotherapy, we used continuous intracerebral
minipump infusions (from day 5 to day 12 post-GL261
transplant) of the alkylating agent TMZ (Figure 7A, bot-
tom). The infusion cannula was placed directly into the
cortex at a distance of 1 mm from the transplant site. Ini-
tial experiments indicated that doses of TMZ higher than
200 μM were toxic for the animals, as shown by weight
loss and high mortality rate. We therefore selected a con-
centration of 140 μM TMZ for the minipump experi-
ments. We found that TMZ significantly prolonged the
length of survival of glioma-bearing mice (Figure 7B). In
particular, the statistical analysis indicated that 2 nM
CNF1 and 140 μM TMZ enhanced animal survival to a
similar extent (Log Rank test, p = 0.003, followed by
Holm-Sidak test; 2 nM CNF1 vs. vehicle, p = 0.02; 140 μM
TMZ vs. vehicle, p = 0.002; 2 nM CNF1 vs. 140 μM TMZ,
p = 0.91; Figure 7B). Lower doses of TMZ (20 μM) were
completely ineffective (data not shown; n = 4).
Higher CNF1 doses produce a dramatic increase in
survival of glioma-bearing mice
We next asked whether an increase in the CNF1 dose
would be effective in further enhancing animal survival.
To this aim, glioma-bearing mice received a single treat-
ment with CNF1 (80 nM; n = 7) five days after GL261
cell inoculation. We found a dramatic increase in sur-
vival, with 57% of the animals injected with 80 nM
CNF1 still alive 60 days after GL261 cell inoculation
(Kaplan-Meier survival analysis, CNF1 80 nM vs. vehicle,
Log Rank test, p < 0.001; Figure 8A). An histopatho-
logical analysis was conducted in the CNF1-treated
glioma-bearing animals surviving over 60 days. Wefound a small tumor located in the deep cortical layers
and surrounded by apparently healthy cortical tissue
(Figure 8B). These data indicate the potential of CNF1 in
halting glioma growth and preserving neuronal structure.
Discussion
The data reported in this manuscript demonstrate the
therapeutic potential of a bacterial protein toxin, CNF1,
in blocking proliferation of glioma cells and prolonging
the survival of glioma-bearing mice. At present, there
are several evidences on the use of targeted toxins to
treat cancer [21]. However, the clinical efficacy of toxins
has mainly been observed in hematological malignan-
cies, but not in solid tumors, including GBM. The toxin
used in this report, CNF1, is produced by certain patho-
genic strains of E. Coli and consists of a N-terminal
binding domain that interacts with membrane receptors
on target cells, a middle translocation domain to enter
the cytosol and a C-terminal catalytic domain [22,23].
The catalytic moiety of CNF1 activates members of the
Rho GTPase family (Rho, Rac and Cdc42) by conversion
(deamidation) of a single glutamine residue into glu-
tamic acid. This aminoacid change impairs GTP hy-
drolysis thus locking the Rho family proteins in their
GTP-bound, active state [22,23]. Depletion of activated
Rho GTPases is then accomplished via ubiquitin-
mediated proteasomal degradation [8].
Since Rho GTPases regulate the dynamics of the actin
cytoskeleton, their activation by CNF1 triggers a rapid
reorganization of F-actin [24]. In particular, proliferating
cells exposed to CNF1 acquire a multinucleated pheno-
type, due to the inhibition of cytokinesis despite ongoing
nuclear division [22,25,26]. We have observed CNF1-
induced multinucleation in either GL261 glioma cells or
Figure 4 Cytotoxic effect of CNF1 on GL261 cells. (A) Percentage
of living GL261 cells after continuous exposure to CNF1 (18 nM).
Data represent means ± SEM (n = 3). Inset: Morphology of GL261
cells treated with CNF1 for 9 days. Scale bar = 5 μm. (B) Percentage
of cells stained only by Annexin V (Ann V + PI-, left columns), stained
only by Propidium Iodide (Ann V- PI+), positive for both markers
(Ann V + PI+) and unlabeled (right columns). The analysis was
performed in untreated GL261 cells (Control, open bars), in GL261
cells serum deprived for 2 days (grey bars), and in GL261 cells
treated with CNF1 for 10 days (green bars). CNF1 induces a very
significant upregulation in the frequency of Annexin V-Propidium
Iodide double labelled cells (one way ANOVA followed by
Holm-Sidak test, p < 0.05).
Figure 5 CNF1 induces senescence in GL261 cells: SA-beta-gal
staining. (A) Representative images of SA-beta-gal staining of GL261
cells after 24 h, 48 h and 72 h of CNF1 treatment. All images were
taken at 20× magnification. Scale bar = 10 μm. Inset: representative
high magnification of a CNF1-treated cell at 48 hours. Scale
bar = 5 μm. (B) Percentage of beta-gal positive cells at the different
time points. Data shown are representative of three independent
experiments (one way ANOVA, p < 0.0001). All data represent
means ± SEM.
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We have also shown that these multinucleated cells de-
generate within about 15 days in vitro.
These data raise the still open question of the identifica-
tion of the pathway(s) by which CNF1 causes cell degener-
ation. Experiments with β-Galactosidase, Annexin V and
Propidium Iodide labelling allow us to conclude that senes-
cence and then necrosis account for CNF1-induced GL261
cell death. This is consistent with the senescent-like pheno-
type (cell enlargement, flattening, increase in size of nuclei
and nucleoli) assumed by cells treated with CNF1 (seeFigure 4A, inset). At the moment, we cannot exclude the
possibility that the autophagy pathway contributes to the
CNF1-induced phenotype. A recent paper indicates the ac-
tivation of the autophagy pathway following the treatment
of glioma cells with pertussis toxin and TMZ [27]. Future
studies are needed to clarify the possible role of autophagy
in the antitumoral action of CNF1.
Since CNF1 is derived from E. coli, it might be argued
that contamination by bacterial products (such as LPS)
could contribute to the observed antineoplastic effects via
the activation of immune responses in the brain [28]. How-
ever, this hypothesis is very unlikely, as the amount of LPS
is our CNF1 preparation was found to be extremely low, in
a range unable to activate macrophages (see Methods).
In GBM and in experimental glioma models, the acti-
vation of Rho GTPases (such as Rac1) has been linked
Figure 6 Multinucleation in CNF1-treated human GBM cell
cultures. Crystal violet staining in untreated (left) and CNF1-treated
(right) tumor-derived primary human cells. Scale bar = 4 μm. In
the high magnification, note the presence of four nuclei in a
CNF1-treated cell.
Figure 7 Comparison of the survival-promoting effects of CNF1
and TMZ in the GL261 glioma model. (A) Experimental protocol.
Tumor induction by GL261 cells was either followed by a single
intracerebral injection of CNF1/vehicle at day 5 (top) or by minipump
delivery of TMZ from day 5 to day 12 (bottom). (B) Kaplan-Meier
survival curves for animals implanted with GL261 cells. Compared to
vehicle-infused mice (black line), CNF1 (green) and TMZ treatment
(red) significantly increased survival (log Rank test followed by
Holm-Sidak test, p < 0.05).
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cules as key therapeutic targets. In this scenario, the
dramatic effect of CNF1 on the actin cytoskeleton
reorganization renders cells virtually immobile, and this
might substantially enhance the anti-tumoral properties
of the toxin. Indeed, we have demonstrated, in the
wound migration assay, that CNF1 dramatically de-
creased the motility of GL261 cells, suggesting a further
potential therapeutic feature of this toxin for its possible
application in the treatment of glioma tumors. This as-
pect is important in the context of glioma treatment, be-
cause glioma cells tend to diffuse profusely into adjacent
healthy tissue. It is well established that CNF1 causes as-
sembly of F-actin in prominent stress fibers and extreme
flattening of the cell body [6,24]. Since cells in motion
need actin dynamics to attach and detach from the
extracellular matrix, actin polymerization by CNF1 ef-
fectively renders cells stationary.
Furthermore, it is worth noting that the other key as-
pect of the action of CNF1 is on neuron plasticity and
health [10]. This cooperates with the antitumoral effect
(reduced proliferation and motility) and may lead to bet-
ter preservation of neuronal function in the brain areas
surrounding the tumor. Experiments to address CNF1-
mediated functional sparing in glioma models are cur-
rently ongoing in our laboratory.
Importantly, a key feature of CNF1 is the rapidity of
its action. We found that exposure to CNF1 for 1 hr was
sufficient to halt proliferation of most of the treated cells
(Figure 2). Since CNF1 is an enzyme, entry of a few toxin
molecules inside a cell can lead to the modification of sev-
eral Rho GTPase targets, providing a dramatic amplifyingeffect. Thus, even a short CNF1 exposure produced nearly
maximal effects on cell proliferation. This may be import-
ant for glioma therapy, as one problem of local therapies
is the rapid washout of therapeutic molecules infused in
the tumor area. Moreover, the effects of CNF1 appear to
persist for weeks following one single administration of
the toxin [10,11,30], likely due to persistent catalytic activ-
ity of the toxin inside cells. This further strengthens the
potential of CNF1 and could avoid the need for repeated
drug administration.
The potential involvement of CNF1 in cell transform-
ation is still controversial [31]. Several studies in vitro
and in vivo, including the present results, demonstrate
the anti-proliferative and cytotoxic effect of CNF1 in
cancer cell lines [22,25,26]. Furthermore, cell transform-
ation and tumor formation have never been observed
Figure 8 Increasing CNF1 doses produces a dramatic
enhancement of survival in glioma-bearing mice. (A)
Kaplan-Meier curves show that treating glioma-bearing mice with a
higher concentration of CNF1 (80 nM) resulted in a very potent
increase in mice survival. Indeed, 57% of mice injected with CNF1 80
nM were still alive 60 days after GL261 cells injection. Data for
control animals are the same reported in Figure 7B. (B) Hoechst
stained coronal section through the visual cortex of a tumor-bearing
mouse treated with CNF1. The tumoral mass in the ventral part of the
cortex does not affect the normal cortical layering. Scale bar = 500 μm.
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(e.g. [10,11,30]).
In order to evaluate the effectivness of CNF1, we com-
pared its action to that of a current standard chemotherapic
drug, namely TMZ. Even if TMZ in experimental animal
models is typically given orally, here we have chosen to ad-
minister it via an intracranial route to allow direct compari-
son with CNF1, which does not cross the blood–brain
barrier. We found that TMZ, administered for one week
via minipumps, was effective in prolonging animal survival
but had a quite narrow therapeutic range, with concentra-
tions of 20 μM being ineffective and concentrations >
200 μM being toxic for the animals. The limited efficacy of
TMZ chemotherapy is in line with current clinical and ex-
perimental experience [4,32] and can be attributed to both
inherent and acquired tumor drug resistance. In contrast
with conventional chemotherapy, CNF1 had greater efficacy
and showed no obvious side effects with increasing doses.
Remarkably, more than half of the animals treated with80 nM CNF1 survived for at least 60 days following
glioma cell inoculation. One important aspect of CNF1
is its long-lasting action, as one single intracerebral ad-
ministration leads to Rho GTPase activation for at least
10–28 days [10,11,30].
Conclusions
In summary, we have exploited the remarkable properties
of CNF1 for interfering with glioma proliferation in vitro
and in vivo. Specifically, we demonstrated in vitro that: (i)
CNF1 blocks proliferation of GL261 cells, (ii) induces cell
senescence and death, (ii) inhibits migration of tumor cells
in the wound assay. In vivo, CNF1 was more effective than
TMZ in prolonging survival of tumor-bearing mice. Given
these antitumoral actions, and the ability of CNF1 to en-
hance learning, memory and plasticity in the intact and dis-
eased brain [10,11,30], the present data suggest that CNF1
might hinder glioma growth and at the same time preserve
neuronal responses in the peritumoral area.
Abbreviations
CNF1: Cytotoxic necrotizing factor 1; TMZ: Temozolomide; GBM:
Glioblastoma multiforme; WHO: World Health Organization; ANOVA: Analysis
of variance; SEM: Standard error of the mean; SA-β-gal: Senescence-associated
β-galactosidase; LPS: Lipopolysaccharide.
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
EV carried out all in vivo experiments, performed the statistical analysis and
drafted the manuscript. AP carried out all in vitro experiments, performed the
statistical analysis and drafted the manuscript. CC partecipated in the in vivo
experiments. SL performed the in vitro experiments with human
glioblastoma cells. EC performed the cell death assays. AF and CF provided
CNF1 toxin. NB and RV provided human biopsies of glioblastoma
multiforme. MCa and MCo conceived of the study, and participated in its
design and coordination and drafted the manuscript. All authors read and
approved the final manuscript.
Authors’ information
Matteo Caleo and Mario Costa are equal contributors as senior authors.
Acknowledgment
This work was supported by AIRC (Italian Association for Cancer Research)
grant # IG 13252 and NanoBrain project (part of the CNR Flagship Project
NanoMax).
Author details
1CNR Neuroscience Institute, Via Moruzzi 1, 56124 Pisa, Italy. 2Scuola Normale
Superiore, Piazza Dei Cavalieri 7, 56100 Pisa, Italy. 3Istituto Superiore di Sanità,
Viale Regina Elena 299, 00161 Rome, Italy. 4Neurochirurgia, Azienda
Ospedaliero-Universitaria Pisana, Via Paradisa 2, 56100 Pisa, Italy.
Received: 22 January 2014 Accepted: 11 June 2014
Published: 18 June 2014
References
1. Khasraw M, Lassman AB: Advances in the treatment of malignant
gliomas. Curr Oncol Rep 2010, 12(1):26–33.
2. Stupp R, Hegi ME, Gilbert MR, Chakravarti A: Chemoradiotherapy in
malignant glioma: standard of care and future directions. J Clin Oncol
2007, 25(26):4127–4136.
3. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG: Gene
therapy and targeted toxins for glioma. Curr Gene Ther 2005, 5(6):535–557.
Vannini et al. BMC Cancer 2014, 14:449 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/4494. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC,
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E,
Mirimanoff RO: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987–996.
5. Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 2002,
420(6916):629–635.
6. Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K: Gln 63 of Rho is
deamidated by Escherichia coli cytotoxic necrotizing factor-1.
Nature 1997, 387(6634):725–729.
7. Flatau G, Lemichez E, Gauthier M, Chardin P, Paris S, Fiorentini C, Boquet P:
Toxin-induced activation of the G protein p21 Rho by deamidation of
glutamine. Nature 1997, 387(6634):729–733.
8. Doye A, Mettouchi A, Bossis G, Clement R, Buisson-Touati C, Flatau G,
Gagnoux L, Piechaczyk M, Boquet P, Lemichez E: CNF1 exploits the
ubiquitin-proteasome machinery to restrict Rho GTPase activation for
bacterial host cell invasion. Cell 2002, 111(4):553–564.
9. Falzano L, Fiorentini C, Boquet P, Donelli G: Interaction of Escherichia coli
cytotoxic necrotizing factor type 1 (CNF1) with cultured cells.
Cytotechnology 1993, 11(Suppl 1):S56–58.
10. Cerri C, Fabbri A, Vannini E, Spolidoro M, Costa M, Maffei L, Fiorentini C,
Caleo M: Activation of Rho GTPases triggers structural remodeling and
functional plasticity in the adult rat visual cortex. J Neurosci 2011,
31(42):15163–15172.
11. Diana G, Valentini G, Travaglione S, Falzano L, Pieri M, Zona C, Meschini S,
Fabbri A, Fiorentini C: Enhancement of learning and memory after
activation of cerebral Rho GTPases. Proc Natl Acad Sci U S A 2007,
104(2):636–641.
12. Zagzag D, Miller DC, Chiriboga L, Yee H, Newcomb EW: Green fluorescent
protein immunohistochemistry as a novel experimental tool for the
detection of glioma cell invasion in vivo. Brain Pathol 2003, 13(1):34–37.
13. Miyatake S, Martuza RL, Rabkin SD: Defective herpes simplex virus vectors
expressing thymidine kinase for the treatment of malignant glioma.
Cancer Gene Ther 1997, 4(4):222–228.
14. Falzano L, Fiorentini C, Donelli G, Michel E, Kocks C, Cossart P, Cabanie L,
Oswald E, Boquet P: Induction of phagocytic behaviour in human
epithelial cells by Escherichia coli cytotoxic necrotizing factor type 1.
Mol Microbiol 1993, 9(6):1247–1254.
15. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic
assay of cells in vitro. Nat Protoc 2006, 1(5):2315–2319.
16. Liang CC, Park AY, Guan JL: In vitro scratch assay: a convenient and
inexpensive method for analysis of cell migration in vitro. Nat Protoc
2007, 2(2):329–333.
17. Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF,
Bronstein JM: Identification of a human glioma-associated growth factor
gene, granulin, using differential immuno-absorption. Cancer Res 2000,
60(5):1353–1360.
18. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR,
Bruce ZC, Lim YC, Offenhauser C, Charmsaz S, Cooper LT, Ellacott JK,
Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G,
Khanna KK, Reynolds BA, Lickliter JD, Boyd AW: EphA3 maintains tumori-
genicity and is a therapeutic target in glioblastoma multiforme.
Cancer Cell 2013, 23(2):238–248.
19. Restani L, Cerri C, Pietrasanta M, Gianfranceschi L, Maffei L, Caleo M:
Functional masking of deprived eye responses by callosal input during
ocular dominance plasticity. Neuron 2009, 64(5):707–718.
20. Lodovichi C, Berardi N, Pizzorusso T, Maffei L: Effects of neurotrophins on
cortical plasticity: same or different? J Neurosci 2000, 20(6):2155–2165.
21. Li YM, Hall WA: Targeted toxins in brain tumor therapy. Toxins (Basel)
2010, 2(11):2645–2662.
22. Fabbri A, Travaglione S, Fiorentini C: Escherichia coli cytotoxic necrotizing
factor 1 (CNF1): toxin biology, in vivo applications and therapeutic
potential. Toxins (Basel) 2010, 2(2):283–296.
23. Aktories K: Bacterial protein toxins that modify host regulatory GTPases.
Nat Rev Microbiol 2011, 9(7):487–498.
24. Fiorentini C, Fabbri A, Flatau G, Donelli G, Matarrese P, Lemichez E, Falzano
L, Boquet P: Escherichia coli cytotoxic necrotizing factor 1 (CNF1), a toxin
that activates the Rho GTPase. J Biol Chem 1997, 272(31):19532–19537.
25. Caprioli A, Falbo V, Roda LG, Ruggeri FM, Zona C: Partial purification and
characterization of an escherichia coli toxic factor that induces
morphological cell alterations. Infect Immun 1983, 39(3):1300–1306.26. Caprioli A, Donelli G, Falbo V, Possenti R, Roda LG, Roscetti G, Ruggeri FM: A
cell division-active protein from E coli. Biochem Biophys Res Commun 1984,
118(2):587–593.
27. Magana-Maldonado R, Manoutcharian K, Hernandez-Pedro NY, Rangel-
Lopez E, Perez-Dela Cruz V, Rodriguez-Balderas C, Sotelo J, Pineda B: Con-
comitant treatment with pertussis toxin plus temozolomide increases
the survival of rats bearing intracerebral RG2 glioma. J Cancer Res Clin
Oncol 2014, 140(2):291–301.
28. Chicoine MR, Won EK, Zahner MC: Intratumoral injection of
lipopolysaccharide causes regression of subcutaneously implanted
mouse glioblastoma multiforme. Neurosurgery 2001, 48(3):607–614.
29. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, Rutka JT:
Inhibition of Rho-kinase affects astrocytoma morphology, motility, and
invasion through activation of Rac1. Cancer Res 2005, 65(19):8792–8800.
30. De Filippis B, Fabbri A, Simone D, Canese R, Ricceri L, Malchiodi-Albedi F,
Laviola G, Fiorentini C: Modulation of RhoGTPases improves the behav-
ioral phenotype and reverses astrocytic deficits in a mouse model of
Rett syndrome. Neuropsychopharmacology 2012, 37(5):1152–1163.
31. Travaglione S, Fabbri A, Fiorentini C: The Rho-activating CNF1 toxin from
pathogenic E. coli: a risk factor for human cancer development?
Infect Agent Cancer 2008, 3:4.
32. Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI: Blood glutamate
scavengers prolong the survival of rats and mice with brain-implanted
gliomas. Invest New Drugs 2012, 30(6):2226–2235.
doi:10.1186/1471-2407-14-449
Cite this article as: Vannini et al.: The bacterial protein toxin, cytotoxic
necrotizing factor 1 (CNF1) provides long-term survival in a murine
glioma model. BMC Cancer 2014 14:449.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
